Universe Pharmaceuticals Inc. (UPC) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Jan 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the UPC SEC filings page.
Universe Pharmaceuticals Inc. (UPC) reported $17.9M in revenue for fiscal year 2025, down 22.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business has shrunk materially, and gross-margin recovery still has not restored cash generation.
Across FY2021-FY2025, revenue contracted sharply while gross margin fell from52.8% to35.3% ; the later improvement is a partial repair, not a return to earlier economics. In FY2025, operating cash flow was-$5.1M against an operating loss of$2.9M , showing that reported losses understated the cash absorbed by operations.
Gross margin improved to
Cash conversion remains weak: FY2025 free cash flow was
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Universe Pharmaceuticals Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Universe Pharmaceuticals Inc. held $33.6M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $5.1M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Universe Pharmaceuticals Inc. scores 73/100 among other emerging companies.
Universe Pharmaceuticals Inc. had 563,338 shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Universe Pharmaceuticals Inc. scores 91/100 among other emerging companies.
Universe Pharmaceuticals Inc. spent $672K on research and development in fiscal year 2025, which was 3.2% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Universe Pharmaceuticals Inc. scores 19/100 among other emerging companies.
Universe Pharmaceuticals Inc. reported revenue of $17.9M in fiscal year 2025, against $23.0M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Universe Pharmaceuticals Inc. scores 15/100 among other emerging companies.
Not available for Universe Pharmaceuticals Inc., and counted as zero in the overall score.
Universe Pharmaceuticals Inc.'s cash, cash equivalents and investments came to $33.6M at the end of fiscal year 2025, against $13.2M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Universe Pharmaceuticals Inc. scores 79/100 among other emerging companies.
Universe Pharmaceuticals Inc. scores 1.52, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($21.5M) relative to total liabilities ($13.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Universe Pharmaceuticals Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Universe Pharmaceuticals Inc. reported a net loss of $3.7M while operations used $5.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Universe Pharmaceuticals Inc. reported an operating loss of $2.9M against $289K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
Universe Pharmaceuticals Inc. held $33.6M in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
UPC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
UPC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F | Q4'2420-F | Q2'2410-Q | Q4'2310-K | Q2'2310-Q | Q4'2210-K | Q2'2210-Q | Q4'2110-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $69.3M+2.0% | $68.0M+62.9% | $49.4M-29.8% | $41.7M-29.9% | $70.4M-1.4% | $59.5M-15.1% | $71.4M | $70.1M+143.5% |
| Current Assets | $53.6M+3.8% | $51.6M+104.3% | $33.5M-36.2% | $25.3M-39.1% | $52.5M+1.7% | $41.5M-17.8% | $51.7M | $50.5M+116.8% |
| Cash & Equivalents | $33.6M+13.9% | $29.5M+458.1% | $8.9M-31.6% | $5.3M-7.5% | $13.0M-9.0% | $5.7M-29.3% | $14.2M | $8.1M-19.7% |
| Short-Term Investments | $0-100.0% | $1.4M-89.6% | $2.5M-81.0% | $13.2M+0.5% | $13.3M-7.2% | $13.1M-4.2% | $14.3M | $13.7M |
| Inventory | $2.2M+26.3% | $1.7M-48.0% | $3.4M+18.1% | $3.3M+51.5% | $2.9M-15.3% | $2.2M-10.4% | $3.4M | $2.5M+29.2% |
| Accounts Receivable | $13.0M+0.8% | $12.9M+17.2% | $14.4M-17.9% | $11.0M-27.5% | $17.5M-6.9% | $15.2M-2.5% | $18.8M | $15.6M+43.2% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $13.2M-41.3% | $22.5M+63.2% | $22.7M-2.4% | $13.8M-43.2% | $23.2M+127.7% | $24.2M+4.6% | $10.2M | $23.2M+189.4% |
| Current Liabilities | $13.2M-35.1% | $20.3M+47.7% | $20.6M-11.3% | $13.8M+5.0% | $23.2M+127.7% | $13.1M+16.8% | $10.2M | $11.2M+40.1% |
| Non-Current Liabilities | $0-100.0% | $2.1M | $2.1M | $0-100.0% | $0 | $11.1M-7.0% | $0 | $11.9M |
| Total Equity | $56.1M+23.4% | $45.5M+62.7% | $26.7M-43.3% | $28.0M-20.8% | $47.1M-22.9% | $35.3M-24.8% | $61.2M | $47.0M+125.9% |
| Retained Earnings | -$13.8M-36.1% | -$10.2M-604.3% | -$2.9M-118.9% | -$1.4M-108.8% | $15.6M-41.7% | $16.3M-34.9% | $26.8M | $25.1M+82.4% |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
UPC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
UPC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Universe Pharmaceuticals Inc. UPC | FY2025 | $17.9M | -$3.7M | -20.6% | $21.5M | 46/100 |
| Akanda Corp. AKAN | FY2025 | $258K | N/A | N/A | $4.3M | — |
| PRF Technologies Ltd. PRFX | FY2025 | $17K | -$5.0M | N/A | $3.0M | — |
| Shuttle Pharmaceuticals Holdings, Inc. SHPH | FY2025 | N/A | -$11.7M | N/A | $26.0M | — |
| Redhill Biopharma Ltd. RDHL | FY2025 | $286K | -$429K | N/A | $4.7M | — |
| cbdMD, Inc. YCBD | FY2025 | $19.2M | -$2.0M | -10.6% | $4.0M | 38/100 |
Where Universe Pharmaceuticals Inc. Ranks
Frequently Asked Questions
What is Universe Pharmaceuticals Inc.'s annual revenue?
Universe Pharmaceuticals Inc. (UPC) reported $17.9M in total revenue for fiscal year 2025. This represents a -22.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Universe Pharmaceuticals Inc.'s revenue growing?
Universe Pharmaceuticals Inc. (UPC) revenue declined by 22.4% year-over-year, from $23.0M to $17.9M in fiscal year 2025.
Is Universe Pharmaceuticals Inc. profitable?
No, Universe Pharmaceuticals Inc. (UPC) reported a net income of -$3.7M in fiscal year 2025, with a net profit margin of -20.6%.
What is Universe Pharmaceuticals Inc.'s EBITDA?
Universe Pharmaceuticals Inc. (UPC) had EBITDA of -$2.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Universe Pharmaceuticals Inc.'s gross margin?
Universe Pharmaceuticals Inc. (UPC) had a gross margin of 35.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Universe Pharmaceuticals Inc.'s operating margin?
Universe Pharmaceuticals Inc. (UPC) had an operating margin of -16.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Universe Pharmaceuticals Inc.'s net profit margin?
Universe Pharmaceuticals Inc. (UPC) had a net profit margin of -20.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Universe Pharmaceuticals Inc.'s return on equity (ROE)?
Universe Pharmaceuticals Inc. (UPC) has a return on equity of -6.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Universe Pharmaceuticals Inc.'s free cash flow?
Universe Pharmaceuticals Inc. (UPC) recorded an outflow of $5.3M in free cash flow during fiscal year 2025. This represents a 45.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Universe Pharmaceuticals Inc.'s operating cash flow?
Universe Pharmaceuticals Inc. (UPC) recorded an outflow of $5.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Universe Pharmaceuticals Inc.'s total assets?
Universe Pharmaceuticals Inc. (UPC) had $69.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Universe Pharmaceuticals Inc.'s capital expenditures?
Universe Pharmaceuticals Inc. (UPC) invested $267K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Universe Pharmaceuticals Inc. spend on research and development?
Universe Pharmaceuticals Inc. (UPC) invested $672K in research and development during fiscal year 2025.
What is Universe Pharmaceuticals Inc.'s current ratio?
Universe Pharmaceuticals Inc. (UPC) had a current ratio of 4.07 as of fiscal year 2025, which is generally considered healthy.
What is Universe Pharmaceuticals Inc.'s debt-to-equity ratio?
Universe Pharmaceuticals Inc. (UPC) had a debt-to-equity ratio of 0.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Universe Pharmaceuticals Inc.'s return on assets (ROA)?
Universe Pharmaceuticals Inc. (UPC) had a return on assets of -5.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Universe Pharmaceuticals Inc.'s P/E ratio?
Universe Pharmaceuticals Inc. (UPC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $21.5M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Universe Pharmaceuticals Inc.'s price-to-sales ratio?
Universe Pharmaceuticals Inc. (UPC) trades at 1.2x sales, its market capitalization divided by revenue of $17.9M revenue, FY2025. The market capitalization is $21.5M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Universe Pharmaceuticals Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Universe Pharmaceuticals Inc. (UPC) held $33.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.1M over that year. Dividing the one by the other, the reported balance equals about 80 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Universe Pharmaceuticals Inc.'s Altman Z-Score?
Universe Pharmaceuticals Inc. (UPC) has an Altman Z-Score of 1.52, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Universe Pharmaceuticals Inc.'s Piotroski F-Score?
Universe Pharmaceuticals Inc. (UPC) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Universe Pharmaceuticals Inc.'s earnings high quality?
Universe Pharmaceuticals Inc. (UPC) reported a net loss of $3.7M while operations used $5.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Universe Pharmaceuticals Inc. cover its interest payments?
Universe Pharmaceuticals Inc. (UPC) reported an operating loss of $2.9M against $289K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Universe Pharmaceuticals Inc.?
Universe Pharmaceuticals Inc. (UPC) scores 46 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.